

## Drug Treatments

Reference Number: F4925  
Date of Response: 05/10/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### Royal Devon's Eastern FOI Office Response

#### Question 1

How many patients were treated by your trust (for any condition) in the last 3 months with the following drugs:

Adalimumab (Amgevita)	<b>95</b>
Adalimumab (Humira)	<b>41</b>
Adalimumab (Hyrimoz)	--
Adalimumab (Idacio)	--
Adalimumab (Imraldi)	<b>521</b>

#### Question 2

How many patients were treated for Hidradenitis Suppurativa in the last 3 months with the following drugs:

Adalimumab (Humira)	<b>*≤5</b>
Adalimumab Biosimilar	<b>24</b>
Infliximab (Remicade)	--
Infliximab Biosimilar	--
Ustekinumab (Stelara)	--
Secukinumab (Cosentyx)	--

#### Question 3

How many patients were treated for Psoriasis in the last 3 months with the following:

Ciclosporin	<b>*≤5</b>
Methotrexate – any form and strength	<b>110</b>
Methotrexate injections 15mg and above	<b>57</b>

**\*≤5 were indicated - In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.**